Agonist
Back to library
GH SecretagogueSubcutaneous

Sermorelin

Also known as: GRF 1-29 · Geref

Synthetic GHRH(1-29) — the minimum bioactive fragment of natural growth hormone-releasing hormone. Stimulates physiologic pulsatile GH release from the pituitary; activity decays in minutes.

At a glance

Half-life
12 minutes
Common route
Subcutaneous
Typical dose range
100–500mcg
Stability (reconstituted)
30days refrigerated

Best timing

Pre-bed on empty stomach to align with natural nocturnal GH peak. Daily dosing common.

Contraindications

  • Active cancer
  • Pituitary disease
  • Pregnancy
  • Hypothyroidism (must be replaced first)

Watch symptoms

  • Flushing at injection site
  • Vivid dreams or sleep disturbance
  • Headache
  • Nausea on first doses
  • Mild lightheadedness

Citations

The primary literature.

  1. 01Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?PubMed
  2. 02Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adultsPubMed
Back to library